MTOR and renal cell adenocarcinoma: Specifically, therapies that have demonstrated benefit in metastatic RCC include the small molecule tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib [8-10], the anti-VEGF antibody bevacizumab [11], temsirolimus and everolimus, inhibitors of mTOR, which has been implicated in HIF transcription [12].